RxDoctor Payments Data

Lexis Carter, PA

Physician Assistant · Johnson City, TNNPI 1922670389

Payments from drug & device makers

$7,150in general payments, 2019–2025

Across 353 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$875
  • GSK$591
  • Actelion Pharmaceuticals US, Inc.$473
  • Boehringer Ingelheim$357
  • Sanofi$356
  • Astellas Pharma US Inc$312
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$6,95897%
  • Education$1913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,150 in reported general payments places this provider in the 90th percentile of 2,404 physician assistant providers in Tennessee.

See all physician assistant providers in Tennessee

Medicare billing

Part B allowed, 2024
$58,002
Medicare patients
444
Services billed
805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate31$463,372
Trelegy ElliptaFluticasone/Umeclidin/Vilanter575$427,894
Aralast NpAlpha-1-Proteinase Inhibitor19$200,277
Breztri AerosphereBudesonide/Glycopyr/Formoterol231$174,412
Dupixent PenDupilumab34$142,151
Spiriva RespimatTiotropium Bromide122$86,646
Stiolto RespimatTiotropium Br/Olodaterol Hcl136$77,392
Dupixent SyringeDupilumab14$61,851
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr107$58,491
Breo ElliptaFluticasone/Vilanterol51$24,670
Spiriva HandihalerTiotropium Bromide32$22,347
Combivent RespimatIpratropium/Albuterol Sulfate36$20,242
SymbicortBudesonide/Formoterol Fumarate67$19,891
Fluticasone-SalmeterolFluticasone Propion/Salmeterol116$17,873
Roflumilast148$16,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$357$647,652325 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$591$517,531751 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$875$204,424319 claims
Johnson & JohnsonXarelto$51$7,83614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,404 physician assistant providers in Tennessee.

Other physician assistant in Johnson City

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →